Literature DB >> 12088296

Surgical management of pancreatic cancer.

Steven A Ahrendt1, Henry A Pitt.   

Abstract

Pancreatic cancer is the fifth leading cause of cancer death in the United States, with an overall survival rate of 3%. Unfortunately, only a minority of patients present with localized disease amenable to surgical resection. Over the past 20 years, improvements in operative and perioperative management have led to a decrease in operative mortality, shorter hospital stay, and overall 5-year survival of approximately 20% in patients undergoing pancreaticoduodenectomy. Despite advances in nonoperative palliation, surgery continues to play an important role in the management of patients with locally advanced, unresectable pancreatic cancer.

Entities:  

Mesh:

Year:  2002        PMID: 12088296

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  24 in total

1.  Diagnostic utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels.

Authors:  Xiaoli Jin; Yulian Wu
Journal:  Afr Health Sci       Date:  2015-03       Impact factor: 0.927

2.  LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice.

Authors:  Rene Hennig; Jacinthe Ventura; Ralf Segersvard; Erin Ward; Xian-Zhong Ding; Sambasiva M Rao; Borko D Jovanovic; Takeshi Iwamura; Mark S Talamonti; Richard H Bell; Thomas E Adrian
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

3.  The case against preoperative biliary drainage with pancreatic resection.

Authors:  Rurik C Johnson; Steven A Ahrendt
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

4.  BART inhibits pancreatic cancer cell invasion by Rac1 inactivation through direct binding to active Rac1.

Authors:  Keisuke Taniuchi; Kunihiko Yokotani; Toshiji Saibara
Journal:  Neoplasia       Date:  2012-05       Impact factor: 5.715

Review 5.  Pancreatic cancer stem cells: features and detection methods.

Authors:  Toshiyuki Ishiwata; Yoko Matsuda; Hisashi Yoshimura; Norihiko Sasaki; Shunji Ishiwata; Naoshi Ishikawa; Kaiyo Takubo; Tomio Arai; Junko Aida
Journal:  Pathol Oncol Res       Date:  2018-06-08       Impact factor: 3.201

6.  The transcription factor HOXB7 regulates ERK kinase activity and thereby stimulates the motility and invasiveness of pancreatic cancer cells.

Authors:  Makiko Tsuboi; Keisuke Taniuchi; Takahiro Shimizu; Motoaki Saito; Toshiji Saibara
Journal:  J Biol Chem       Date:  2017-09-14       Impact factor: 5.157

7.  Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines.

Authors:  Jonathan P Celli; Nicolas Solban; Alvin Liang; Stephen P Pereira; Tayyaba Hasan
Journal:  Lasers Surg Med       Date:  2011-09       Impact factor: 4.025

8.  Novel therapeutic approaches for pancreatic cancer by combined targeting of RAF→MEK→ERK signaling and autophagy survival response.

Authors:  Faustino Mollinedo; Consuelo Gajate
Journal:  Ann Transl Med       Date:  2019-07

9.  Interferon receptor alpha/beta is associated with improved survival after adjuvant therapy in resected pancreatic cancer.

Authors:  Reza F Saidi; Stephen G Remine; Michael J Jacobs
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

10.  BCL7B, a predictor of poor prognosis of pancreatic cancers, promotes cell motility and invasion by influencing CREB signaling.

Authors:  Keisuke Taniuchi; Mutsuo Furihata; Seiji Naganuma; Ken Dabanaka; Kazuhiro Hanazaki; Toshiji Saibara
Journal:  Am J Cancer Res       Date:  2018-03-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.